Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced progress in its next-generation trispecific programs. The Company is optimizing several trispecific candidates for reliable, scalable manufacturing, an essential step toward future human...
Read more








